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The influence of macrophage depletion on ligament healing
GCTS
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Macrophage depletion alters ligament healing
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Abstract
Despite a complex cascade of cellular events to reconstruct damaged extracellular matrix (ECM), ligament healing
results in a mechanically inferior, scar-like tissue. During normal healing, the number of macrophages significantly
increases within the wound site. Then, granulation tissue expands into any residual, normal ligamentous tissue
(creeping substitution), resulting in a larger region of healing, greater mechanical compromise, and an inefficient
repair process. To study the effects of macrophages on the repair process, bilateral, surgical rupture of their medial
collateral ligaments (MCLs) was done on rats. Treatment animals received liposome-encapsulated clodronate, 2 days
before rupture to ablate phagocytosing macrophages. Ligaments were then collected at days 5, 11, and 28 for immunohistochemistry (IHC) and/or mechanical testing. Clodronate treatment reduced both the M1 and M2 macrophages
at day 5 and altered early healing. However, the macrophages effectively returned to control levels after day 5 and
reinitiated a wound-healing response. Our results suggest that an early macrophage response, which is necessary for
debridement of damaged tissue in the wound, is also important for cytokine release to mediate normal repair processes. Additionally, nonspecific inhibition of macrophages (without regard to specific macrophage populations) can
control excessive granulation tissue formation but is detrimental to early matrix formation and ligament strength.
Keywords: ligament healing, clodronate, macrophage, immunohistochemistry, rat

INTRODUCTION
Normal ligament healing after rupture undergoes
inflammation, proliferation, and remodeling. Initially
neutrophils, macrophages, and T-lymphocytes infiltrate
the wound followed by fibroblasts, myofibroblasts,
endothelial cells, and additional macrophages. These
cells form granulation tissue which expands to remodel
residual extracellular matrix (ECM), that is, “creeping
substitution,” damaging intact portions of the ligament
contributing to an inefficient healing response [1]. As
healing continues, type I procollagen decreases whereas
type III collagen increases (manuscript in review). The
newly formed type III collagen serves as a weak transient
bridge for the injured ligament. As remodeling continues,
the scar matures and the ratio of type I to type III
collagen normalizes, improving the tensile strength of
the compromised region, but the ligament never fully
returns to its original state [2,3]. In an improved
healing scenario, granulation tissue would develop
without excessive creeping substitution, collagen type I

would regenerate rapidly, and native tissue would
regenerate to demonstrate pre-damage laxity and
strength.
Macrophages are a heterogeneous group of cells
having different phenotypes and functions. During
creeping substitution, macrophages accumulate within
the healing region to play a central role in wound healing
via phagocytosis of cellular debris, apoptosis, inflammatory cell and myofibroblast recruitment, angiogenesis
regulation, and scar tissue formation. Three distinct
populations of activated macrophages are known to
exist: classically activated, alternatively activated, and
regulatory macrophages. Classically activated (M1)
macrophages participate in cellular debris clearance,
host defense, and pro-inflammatory cytokine release.
Alternatively activated (M2) macrophages less effectively
kill pathogens, but instead secrete components of
ECM, produce anti-inflammatory cytokines, and are
involved primarily in the wound-healing response.
Regulatory (type II) macrophages have been recently
distinguished from the M2 phenotype. These type II
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macrophages retain the ability to produce proinflammatory cytokines, but they simultaneously
inhibit inflammation. They do not contribute to ECM
production and are considered pertinent in immune
regulation. Collectively, the macrophage populations
form a carefully balanced regulatory network for the
immune responses as the healing process progresses.
Although the multifunctional role of macrophages is
generally well reported, a more detailed understanding
of their intricate role in ligament healing could generate
new therapeutic approaches and clinical treatments.
The beneficial influence of macrophages during
healing is controversial. Many suggest that the invading
cells are detrimental to regeneration [4–8]. The presence
of macrophages and their resultant cytokines have been
linked to chronic inflammation and tissue fibrosis
[7,9,10]. Conversely, embryonic wounds heal scar-free,
repairing without the presence of immune cells [11,12].
Our prior research correlating macrophages with creeping
substitution and delayed/impaired ligament healing
strongly suggested that macrophages significantly affect
healing in the ligament [1]. The objective of this study
was to determine the functional and biological
relevance of macrophages during ligament healing
using a surgically disrupted medial collateral ligament
(MCL) rat model. We hypothesized that eliminating
the macrophage populations after injury would alter
inherent ligament wound healing and subsequent
remodeling. Clodronate, a well-known inhibitor of
macrophages, was liposome-encapsulated and administered intravenously (IV) to rats. Non-encapsulated
clodronate is nontoxic, does not cross cell membranes,
and has an extremely short half-life in the circulation.
In vivo administration of clodronate-encapsulated
liposomes results in the phagocytosis of liposomes by
the macrophages/monocytes. Lysosomal enzymes of
the macrophages/monocytes degrade the liposome and
macrophages undergo apoptosis after exposure to
clodronate, creating a macrophage-depleted tissue.
After successful macrophage depletion, alterations in
the ligament healing response were determined.
MATERIALS AND METHODS
Animals

This study was approved by the University of Wisconsin
Institutional Animal Use and Care Committee.
Thirty-eight skeletally mature male Wistar rats (275–299 g)
were used as an animal model for ligament healing.
The MCL was chosen as a model for extra-capsular
ligament healing. All rats were purchased with fitted
external jugular catheters to facilitate IV treatment
administration.
Surgical procedure

Rats were separated into two treatment groups (n = 19
rats/treatment group). Two days prior to surgery,

animals were administered 1 mL/100 g body weight
liposome-encapsulated clodronate (Clod-Lip) or liposome-encapsulated phosphate-buffered saline (PBS)
which serves as the control (PBS-Lip). All rats were
then subjected to bilateral transection (day 0) of the
MCL. Rats were anesthetized using isofluorane.
A surgically transected, rather than torn, MCL was
used as an experimental model to create a uniform
defect for healing. A 1 cm skin incision was made over
the medial aspect at both the left and right stifles. The
subcutaneous tissue was dissected to expose the
sartorius muscle and underlying MCL. The mid-point
of the MCL (determined using a scaled scalpel handle)
was completely transected and the muscular, subcutaneous, and subdermal tissue layers were each closed
with 4-0 Dexon suture. All animals were allowed unrestricted cage movement immediately after surgery. At
5, 11, and 28 days post-injury, animals were sacrificed
and the MCLs collected. MCLs were assayed via
immunohistochemistry (IHC) and mechanical testing.
Three animals per treatment were used for IHC and
histology, and five animals per treatment were used for
mechanical testing at each time point except for day 5.
Mechanical testing was not performed on day 5 because
the ligament was too structurally compromised for
meaningful data with our methods of in vitro testing.
Macrophage depletion

Circulating monocytes/macrophages were reduced
in vivo using clodronate (dichloromethylene bisphosphonate). Clodronate was a gift of Roche Diagnostics
GmbH (Mannheim, Germany) and was encapsulated into liposomes as previously described [13].
Animals received one IV injection (1 mL/100 g body
weight) of liposome-encapsulated clodronate or
liposome-encapsulated PBS, 2 days prior to injury.
Tissue harvest

At the time of sacrifice, the MCLs used for IHC were
carefully dissected, measured, weighed, and immediately
placed in optimal cutting temperature (OCT) medium
for flash freezing. Longitudinal cryosections were then
cut at a 5 μm thickness, mounted on Superfrost plus
microscope slides (Fisher Scientific, Pittsburgh, PA,
USA) and maintained at −70°C. Animals used for
mechanical testing were sacrificed and limbs were
stored in toto at −70°C until used.
Histology

Ligament cryosections were H&E stained to observe
general morphology of the healing ligaments. After
staining, images were captured and the granulation
tissue regions were measured using Image J (National
Institutes of Health, NIH, Bethesda, MD, USA).
Granulation tissue area was normalized to the total
MCL area and expressed as the percent normalized
granulation tissue.

Immunohistochemistry/immunofluorescence (IHC/IF)

Immunostaining was performed on frozen sections
using mouse monoclonal or rabbit polyclonal antibodies.
Cryosections were fixed for 10 min with acetone,
exposed for 5 min to 3% hydrogen peroxide to eliminate
endogenous peroxidase activity, blocked for 30 min with
Background Buster (Innovex Biosciences, Richmond,
CA, USA) and incubated with rabbit or mouse primary
antibody. Sections were then incubated with biotin,
and streptavidin-conjugated to horseradish peroxidase
using the Stat Q staining kit (Innovex Biosciences).
The bound antibody complex was then visualized
using diaminobenzidine (DAB). Stained sections were
dehydrated, cleared, cover-slipped, and viewed using
light microscopy. M1 macrophages were also stained
using double immunofluorescence (IF) to compare
total day 5 cell numbers with M1 macrophages. For IF,
sections were stained with mouse monoclonal antibody
CD68, incubated with goat anti-mouse Alexa Fluor
555 secondary antibody (1:200, Invitrogen, Eugene,
OR, USA), and mounted in Prolong Gold anti-fade
reagent containing DAPI (Invitrogen). Negative controls
omitting the primary antibody were included with each
experiment. Positive controls of gut or spleen were also
included.
Mouse monoclonal antibodies to cell surface markers,
CD68, CD163, and CD3 were utilized to identify the
following leukocytes, respectively: classically activated
macrophages (M1), alternatively activated macrophages
(M2), and T-lymphocytes (all from Abcam-Serotec,
Raleigh, NC, USA, at a dilution of 1:100). Molecular
markers for type II macrophages remain scarce and
were not used in this study. To identify collagen
production, type I procollagen (straight; SP1.D8;
Developmental Hybridoma, Iowa City, IA, USA) and
type III collagen (1:8000, Sigma-Aldrich, St. Louis,
MO, USA) mouse antibodies were used. Endothelial
cells were identified using the polyclonal rabbit antibody
thrombomodulin (1:2500; American Diagnostica,
Stamford, CT, USA) and myofibroblasts were identified
using α-smooth muscle actin (straight; Abcam-Serotec).
Quantification

After IHC/IF staining, micrographs were collected
using a camera-assisted microscope (Nikon Eclipse
microscope, Melville, NY, model E6000 with an
Olympus camera, model DP79). Six blocked random
pictures were obtained from each stained cryosection.
Images were captured at the healing region (HR), distal
healing region (dHR), and proximal healing region
(pHR) edges, epiligament (EL), and distal (distal) and
proximal (prox) ends of the MCL (Figure 1). Two to
three sections were counted per animal. Each captured
image for granulation tissue size, endothelial cells,
myofibroblasts, type I procollagen, and type III collagen was then quantified with Image J (NIH). Images
captured for T-lymphocytes, and M1 and M2 macrophages were quantified manually.

Figure 1. Representative cross-section of the H&E-stained
MCL, indicating the approximate locations; images were captured
for later cell enumeration. Two to three sections from each
animal were captured accordingly (HR, healing region; pHR,
proximal healing region; dHR, distal healing region; prox, proximal;
EL, epiligament; original magnification 400×).

Mechanical testing

The functional mechanical properties of the ligament
were tested to determine the influence of macrophage
inhibition on mechanical performance. Pull-to-failure
testing was performed as previously described by
Provenzano et al. [14–16]. After killing the rats, the
MCL was removed with both femoral and tibial insertion
sites intact and the surrounding tissue was carefully
excised with special care being taken to avoid damaging
the insertion sites. During preparation, the femur–
MCL–tibia (FMT) complex was kept hydrated using
PBS. The width and thickness of the ligament was
measured optically and the cross-sectional area for the
ligament was estimated assuming an elliptical crosssection. The FMT complex was mounted in a custommade testing bath and mechanical testing machine.
Optical markers were applied to the ligament on the
insertion sites and the displacement was recorded optically. A pre-load of 0.1 N was applied to the ligament
and the MCL was preconditioned (cyclically loaded to
1% strain for 10 cycles). Dimension measurements for
the ligament were recorded at the pre-load. The ligament was then pulled to failure at a rate of 10% strain
per second.
Failure force was recorded as the highest load prior
to failure of the ligament and failure stress was calculated
by dividing the failure force by the initial cross-sectional
area of the ligament. Failure strain was calculated by
subtracting the initial ligament length from the ligament
length at failure divided by the initial length of the
ligament.
Statistical analysis

Images for each antibody were obtained at the HR,
pHR, dHR, prox, distal, and EL from two to three
sections per animal with three animals per treatment
per day (e.g., see Figure 1). To determine any spatial
treatment differences within the ligament, regions
were subgrouped into the total, MCL, granulation

tissue, ligament ends, or epiligament regions. The
total region comprises the average of all images
within the MCL (combined average of HR, pHR,
dHR, prox, distal, and EL). The MCL region
includes the average of all the groups excluding the
epiligament. Granulation tissue includes the HR,
pHR, and dHR regions. The ligament ends include
the prox and distal ends (away from the granulation
tissue). Finally, the epiligament only takes into the
account the epiligament measurements. All IHC
assays were analyzed using one-way analysis of variance (ANOVA) to compare the means of the total,
MCL, granulation tissue, ligament ends, and epiligament regions between the PBS-liposome- and clodronate-liposome-treated groups. Specifically, an F-test
was used for testing the overall difference among
treatments. A pairwise-contrast F-test was used for
testing the pairwise differences between groups.
These analyses were conducted using the statistical
software package R-2.9.1. Mechanical testing data
were analyzed via t-tests, using Microsoft Office
Excel (2007).
RESULTS
Morphological measurements/granulation tissue size

To determine if creeping substitution was altered by
macrophage inhibition, the size of the granulation tissue
region was measured by normalizing it with the total
ligament area. At no time interval under investigation
was the normalized granulation tissue size of the
clodronate-liposome-treated animals significantly different from the PBS-liposome controls (Figure 2; p > 0.05).

The PBS-treated granulation tissue area significantly
enlarged from day 11 to day 28 (p < 0.05), whereas
significant enlargement of the clodronate-treated granulation tissue was only observed when comparing day 5
and day 28 samples (p < 0.05). Additionally, day 5
ligaments exposed to clodronate-liposomes weighed
significantly less compared to the PBS-liposometreated animals (p < 0.05). No other time points
showed significant differences.
Macrophage depletion

To evaluate the spatial and temporal effects of
clodronate-liposome treatment on classically and alternatively activated macrophage production, IHC was
performed to identify M1 and M2 macrophages, respectively (Figure 3A–D). Clodronate-liposome treatment
depleted M1 cells within the day 5 MCL (Figure 3A);
the effects were specifically observed within the granulation tissue and ligament ends (Figure 3B). Double
immunofluorescence of the M1 macrophages and
overall cells further indicates the depletion of macrophages by clodronate at day 5 (Figure 3C). By day 11, M1
cells within the MCL were not significantly different
except within the ligament ends (Figure 3A and 3B).
The inhibitory effects of Clod-Lip treatment were no
longer observed at day 28 and significantly more M1
cells were present in the Clod-Lip group versus control
(Figure 3A; p < 0.05). The overall M2 cell numbers
were likewise reduced by Clod-Lip treatment, but no
specific differences were indicated within the granulation
tissue or ligament ends (Figure 3D). No significant
treatment changes were observed by the M1 or M2 cells
within the epiligament at any day (p > 0.05).
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To determine if macrophage depletion influences
T-lymphocyte numbers, tissue sections were subjected to
CD3 IHC, identifying mature T-lymphocytes (Figure 4).
Very few T-lymphocytes were detected in the healing
ligament, regardless of treatment or time of collection.
T-lymphocytes were greatest in number at day 5 and
decreased thereafter. Macrophage inhibition did not
appear to have any influence (p > 0.05) on T-lymphocyte
production.

0
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Figure 2. Graph of the normalized granulation tissue size at 5,
11, and 28 days post-injury after treatment with liposome-encapsulated clodronate (Clod-Lip) or liposome-encapsulated PBS
(PBS-Lip). Between treatments, granulation tissue area did not
change in response to macrophage inhibition (p > 0.05). Within
treatments, granulation tissue area experienced a significant
change between the day 5 and day 28 samples after clodronateliposomes. In contrast, granulation tissue growth was most significant between day 11 and day 28 after PBS-liposome treatment.
*Indicates significance between the day 11 and day 28 PBSliposome groups. §Indicates significant difference between the
day 5 and day 28 clodronate-liposome-treated samples.

Endothelial cell and myofibroblast production

Granulation tissue formation involves an increase in
vascularity, myofibroblasts, and fibroblasts. To evaluate
the effects of macrophage inhibition on granulation
tissue factors, endothelial cell and myofibroblast localization was analyzed. Similar to normal granulation
tissue formation [1], both cell types were increased at
day 11. Macrophage inhibition significantly reduced
endothelial cell and myofibroblast numbers in the day 5
healing ligament (Figure 5A–C; p < 0.05). By day 11
and day 28, MCL endothelial cells were similar between
the Clod-Lip and PBS-Lip groups. Myofibroblasts in
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Figure 3. Graph of the M1 macrophages within the MCL (A), granulation tissue and ligament ends (B) at 5, 11, and 28 days post-injury.
Double immunofluorescence image of total cells and M1 macrophages after PBS-liposome- or clodronate-liposome-treatment (C).
Graph of the MCL M2 macrophages at 5, 11, and 28 days post-injury after liposome-encapsulated clodronate treatment (D). (A)
Clodronate-liposomes (Clod-Lip) reduced MCL M1 macrophages 5 days post-injury compared to the PBS-liposome controls (PBS-Lip)
but increased cells at 28 days post-injury (p < 0.05). (B) Within the MCL, clodronate-liposome treatment reduced M1 macrophages
within the granulation tissue (GT Clod-Lip) and ligament ends (LE Clod-Lip) at day 5 but only depleted macrophages within the ligament ends on day 11. Both LE- and GT-clodronate-liposome-treated regions experienced an increase in M1 macrophages at day 28. (C)
Representative day 5 MCL images of DAPI (top row) and M1 macrophage (bottom row) double immunoflourescence comparing the
number of M1 macrophages to total cells after PBS-liposome (left column) or clodronate-liposome (right column) administration. (D)
Clodronate-liposomes (Clod-Lip) reduced M2 macrophages at day 5, but no other time points were significant. *Indicates significance
(p < 0.05) between Clod-Lip and PBS-Lip at day 5 (A, B, D) and day 28 (A). Values are expressed as mean cell numbers ±SEM.

the granulation tissue tended (p = 0.057) to remain low
at day 11 after clodronate-liposome treatment, suggesting
a prolonged inhibitory effect on myofibroblasts but not
endothelial cells. No treatment differences were
observed at day 28.
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Figure 4. Response of T-lymphocytes to liposome-encapsulated
clodronate (Clod-Lip) or liposome-encapsulated PBS (PBS-Lip)
treatment. Macrophage depletion did not significantly influence
ligament T-lymphocytes across time (p > 0.05). Values are
expressed as mean cell numbers ±SEM.

The native MCL is primarily composed of type I
collagen, whereas type III collagen is indicative of scar
formation. To evaluate the effects of macrophage
depletion on collagen production, IHC for type I
procollagen and type III collagen was performed. Macrophage depletion stimulated total type I procollagen
(p < 0.05) at day 5 but was ineffective thereafter
(Figure 6A; p < 0.05). Additionally, macrophage inhibition spatially and temporally influenced type III
collagen localization (Figure 6B). At day 5, the lower
levels of macrophages resulted in an increase in type III
collagen within the granulation tissue; no other regions
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Figure 5. Endothelial cell (A) and myofibroblast (B) response to liposome-encapsulated clodronate (Clod-Lip) or liposome-encapsulated PBS
(PBS-Lip) treatment. (A) Macrophage depletion significantly suppressed endothelial cells at day 5 (p < 0.05). (B) Myofibroblasts significantly decreased at day 5 (p < 0.05) and tended to decrease at day 11 (p = 0.056) after clodronate-liposome treatment. Treatment did
not significantly influence endothelial cells or myofibroblasts at day 28 post-injury (p > 0.05). (C) Representative images of endothelial
cell (right column) and myofibroblast (left column) IHC after PBS-liposome treatment (top row) or clodronate-liposome (bottom row)
treatment (C). *Indicates significant difference (p < 0.05) between Clod-Lip and PBS-Lip at day 5. #Indicates a trend (p = 0.056)
between Clod-Lip and PBS-Lip at day 11. Values are expressed as mean cell numbers ±SEM.

were affected. By day 11, Clod-Lip reduced type III
collagen within the granulation tissue and ligament
ends. Type III collagen remained decreased within the
ligament ends and epiligament (data not shown) but
not the granulation tissue at day 28.
Spatial localization of IHC factors

To target any cellular or ECM spatial differences after
clodronate-liposome treatment, the total ligament,
MCL body, granulation tissue, ligament ends (outside
of the granulation tissue), and the epiligament were
analyzed. Treatment primarily affected IHC factors
within the MCL body, including both the granulation
tissue and ligament ends. Clodronate-liposome treatment
only influenced epiligament day 28 type III collagen
and day 5 myofibroblasts. The spatial and temporal
M1 macrophage and type III collagen results are of
particular interest. Macrophage cell number reduction
was initially observed within the MCL body (excluding
the epiligament). By day 11, only the M1 macrophages
within the ligament ends were significantly different.
Additionally, type III collagen decreased within the
MCL by day 11. Levels remained low within the ligament
ends on day 28. These results suggest transient

macrophage inhibition altered the typical creeping
substitution pattern and downstream localization of
type III collagen.
Mechanical testing

Analysis of the ligament mechanics after clodronateliposome treatment revealed changes in ligament healing.
Failure force for a ligament is an indicator of ligament
healing, because structural behavior is dependent on
the collagen content and organization. The compositional and micro-structural changes induced by
clodronate-liposome treatment significantly decreased
the ultimate failure force at day 11 (p < 0.05) but had
no effect at day 28 (p > 0.05) when compared to the
PBS-liposome-treated ligaments (Figure 7). This drop
in force indicates the early depletion of macrophages
compromises mechanical strength, but these effects are
transient. No differences were observed in failure stress
or stiffness between treatment groups (Figure 7B and 7C).
DISCUSSION
The aim of this study was to determine the biological
and functional effects of early macrophage depletion on
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Figure 6. Type I procollagen (A) and type III collagen (B) at 5,
11, and 28 days post-injury after liposome-encapsulated clodronate
(Clod-Lip) or liposome-encapsulated PBS (PBS-Lip) treatment. (A) Macrophage depletion significantly increased total
type I procollagen (A) at day 5 (p < 0.05). (B) Within the granulation tissue (GT Clod-Lip), clodronate-liposome treatment initially
increased type III collagen at day 5. Levels then decreased within
the granulation tissue (GT Clod-Lip) and/or ligament ends (LE
Clod-Lip) at day 11 and 28 when compared to PBS-liposome
treatment (GT PBS-Lip, LE PBS-Lip). *Indicates significant difference (p < 0.05) between Clod-Lip and PBS-Lip. Values are
expressed as mean collagen/mm2 ±SEM.

ligament healing. Our previous research established a
localized increase in the M1 macrophages during
ligament creeping substitution [1]. Therefore, we
hypothesized that early depletion of macrophages
would significantly alter ligament healing and scar formation. Liposome-encapsulated clodronate is commonly used for macrophage depletion and angiogenesis
inhibition [17,18]. Our results demonstrated that a single clodronate-liposome injection did not fully ablate
the M1 and M2 macrophages, but significantly reduced
numbers in a spatial and temporal manner. The reduction
in macrophages was sufficient to decrease myofibroblasts
and endothelial cells and to increase type I procollagen at
day 5. Although a single dose of clodronate–liposome was
not able to maintain macrophage inhibition till day 28, the
early inhibition of macrophages resulted in a later
decrease in type III collagen and ligament strength. These
results support the role of macrophages in controlling
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Figure 7. Response of failure force (A), failure stress (B), and
stiffness (C) to liposome-encapsulated clodronate (Clod-Lip) or
liposome-encapsulated PBS (PBS-Lip) treatment. Macrophage
inhibition reduced failure force at day 5 (p < 0.05). No significance in failure stress (B) or stiffness (C) was observed. *Indicates significant difference (p < 0.05) between Clod-Lip and
PBS-Lip at day 5. Values are expressed as mean output ±SEM.

angiogenesis, fibroblast differentiation, and collagen production during early ligament healing.
Scar formation is a balance between ECM production
and degradation. A desired healing scenario after injury
would have little or no scar tissue, organized collagen
fibers, restored concentrations of type I collagen, and
limited creeping substitution. Such behavior, we
hypothesize, would reduce type III collagen and regenerate the ligament with nearly normal composition and
mechanical properties. The M1 macrophages produce

fibrogenic factors such as TGF-β and PDGF to stimulate
the differentiation of fibroblasts to myofibroblasts and
produce ECM proteins. Activated myofibroblasts
subsequently stimulate wound contraction and collagen
production, resulting in ECM turnover and scar formation [19–21]. Additionally, macrophages modulate
matrix metalloproteinases (MMPs) and tissue inhibitors
of MMPs (TIMP) [22]. Inhibition of MMP activity
was found to improve collagen fiber continuity and biomechanical strength of the healing ligament [23]. In the
current study, depletion of macrophages resulted in
upregulated type I procollagen (although concentrations
are unknown) and reduced type III collagen and myofibroblasts, but these changes were either transient or
not sufficient to improve ligament strength. Horn et al.
showed that multiple clodronate-liposome injections
over time inhibit macrophages and control axonal
retraction (a process physically similar to ligament
creeping substitution) between days 4 and 7 post-injury
[8]. We did not repeatedly inject our animals. Perhaps
the remaining macrophages after one treatment and
the later influx of M1 cells may have sufficiently
maintained the creeping substitution phenomenon in
the residual native tissue.
Clodronate-liposomes are commonly used in vivo
to reduce the number of macrophages [6–8,24,25].
Liposome-encapsulated clodronate, used in this study,
cannot cross the vascular endothelium of capillaries
and has no access to the currently inhabiting resident
macrophages. However, monocytes in the circulation
are depleted after IV administration of clodronateliposomes; any circulating monocytes/future resident
cells migrating to the injury will be inhibited. Therefore,
clodronate-liposomes initially and nonspecifically deplete
all circulating phagocytosing macrophages and monocytes rather than specific phenotypes of macrophages.
Macrophages confer remarkable plasticity and
respond to the cytokine environment by modulating
their phenotype and functionality. To date, three
different macrophage populations with distinct biological
functions have been identified: the M1, the M2, and
the type II-activated macrophages (for review see [26]).
Activated M1 cells promote ECM degradation by producing nitric oxide, acquiring an enhanced capability to
kill intracellular microorganisms, and stimulating a
number of pro-inflammatory cytokines. The combination
of IFN-γ and TNF-α stimulates the M1 macrophages.
Macrophage phagocytosis of apoptotic cells results in a
phenotypic transition from an M1 to an M2 macrophage
phenotype [27]. The M2 macrophages promote angiogenesis and matrix remodeling by releasing antiinflammatory cytokines and inhibiting nitric oxide
release. An experiment inhibiting gene expression of
the M2 macrophages, but not the M1 macrophages,
reported the removal of necrotic tissue from injured
tissue, but severe defects in repair [28]. These results
substantiate the functional difference of the macrophage
classes. The less-known type II-activated macrophages

are stimulated by the combination of Fcγ receptors and
the toll-like receptors. Activation of the type II
macrophages induces an anti-inflammatory response
and a Th2-like response that may be used to suppress
autoimmune diseases. Based on these functional characterizations, modulation of the specific macrophage
phenotypes may offer better control over healing rather
than nonspecific macrophage inhibition. Our study
further demonstrates that clodronate-liposomes do not
distinguish the different macrophage phenotypes and
overall depletion produced suboptimal mechanical
properties. Thus, an optimal regenerative environment
may involve a timed inhibition of the M1 macrophages
and a concomitant stimulation of the M2 macrophages
(rather than the nonspecific depletion).
Bone–tendon healing and chronic fibrosis models
improve healing after macrophage inhibition unlike the
MCL model [7,9,10]. During normal healing,
macrophage infiltration is important for wound debridement and subsequent cytokine production. In contrast,
chronic fibrosis represents an exaggerated macrophage
response in the absence of a wound to debride. Macrophage inhibition during chronic fibrosis permits
downregulation of the imposing inflammatory and
fibrotic signals with no need of ablating the cells necessary
for wound debridement. Conversely, inhibition of macrophages before debris clearance in this study stimulated
some repair factors but reduced ligament strength. Our
results contrast with Hays et al. [7], who demonstrated
improved healing after macrophage depletion in a
reconstructed anterior cruciate ligament (ACL) bone–
tendon model. The disparity in results may be attributed to the different experimental models used (tendon
to bone healing versus ligament to ligament healing).
A number of studies have successfully used bisphosphonates in bone healing [29,30]. ACL reconstruction
involves tendon–bone interface healing. Clodronateliposome administration to the reconstructed ACL
model may have ablated the osteoclasts, thereby stimulating an altered repair process in bone versus soft tissue. Bone is also highly vascular compared to the
ligament. Generally, tissues with more vascularity
exhibit better healing than avascular tissues. Additionally, the inflammatory response is extended for a greater
time period within the ACL reconstruction model than
the MCL healing model (because the ACL graft is avascular to start with and the synovial environment delays
remodeling). Similar to the fibrotic model, general inhibition of the inflammatory response in a reconstructed
ACL appears more beneficial than in an MCL.
In conclusion, early macrophage depletion limits
granulation tissue formation and appears to alter downstream scar formation but not without compromising
ligament strength. To improve the biological and
mechanical function of the healing ligament, modulation
of the specific macrophage phenotypes rather than
nonspecific depletion may be a more productive path to
reduce scar formation and regenerate the native tissue.
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